<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04289727</url>
  </required_header>
  <id_info>
    <org_study_id>AAAS5630</org_study_id>
    <nct_id>NCT04289727</nct_id>
  </id_info>
  <brief_title>Skeletal Fragility in Type 1 Diabetes: Glycemic Control and Bone Strength</brief_title>
  <official_title>Skeletal Fragility in Type 1 Diabetes: Glycemic Control and Bone Strength</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to find out how bones are affected in children and&#xD;
      adolescents with type 1 diabetes (T1D) as compared to children and adolescents without type 1&#xD;
      diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      T1D is primarily associated with decrements in bone strength due to disrupted&#xD;
      microarchitecture occurring during peak bone mass accrual, and this disruption arises from&#xD;
      hyperglycemia and glycemic variability. Impaired bone development during this period likely&#xD;
      predisposes to an increased fracture risk across the lifespan.&#xD;
&#xD;
      The investigators will compare baseline, 12 month and 24 month changes in High-resolution&#xD;
      peripheral quantitative computed tomography/micro-finite element analysis&#xD;
      (HR-pQCT/μFEA)-based estimates of bone strength and bone turnover by biochemical measurements&#xD;
      in 40 T1D children at the onset of peak bone mineral accretion (n=40) versus sex and&#xD;
      puberty-matched healthy controls (n=40). The investigators will determine relationships&#xD;
      between changes in bone strength (including trabecular and cortical components) and measures&#xD;
      of glycemic control and variability by continuous glucose monitoring (CGM).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in microarchitecture by HR-pQCT</measure>
    <time_frame>Two Years</time_frame>
    <description>Measures of HRpQCT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in bone mineral density by Dual X-ray Absorptometry (DXA)</measure>
    <time_frame>Two Years</time_frame>
    <description>Measures of DXA</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Type1diabetes</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <description>Those with Type 1 Diabetes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <description>Those without Type 1 Diabetes.</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      am fasting Comprehensive Metabolic Panel (CMP) including liver function, HbA1c and 25OHD.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        40 children and adolescents between the age of 8 to 14 years with type 1 diabetes and 40&#xD;
        children and adolescents between the age of 8 to 14 years without type 1 diabetes.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria (T1D and Controls):&#xD;
&#xD;
        - Children within 2 years preceding the onset of the pubertal growth spurt&#xD;
&#xD;
        Inclusion Criteria (T1D participants):&#xD;
&#xD;
        - documentation of β-cell autoimmunity and need for insulin replacement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR)&lt; 60 ml/mim&#xD;
&#xD;
          -  25(OH)D level &lt; 20 ng/ml.&#xD;
&#xD;
          -  Celiac disease&#xD;
&#xD;
          -  Autoimmune thyroid disease&#xD;
&#xD;
          -  Addison's disease&#xD;
&#xD;
          -  History of pathological fractures&#xD;
&#xD;
             -- Disorders associated with altered skeletal structure or function&#xD;
&#xD;
          -  Bone active drugs in past year&#xD;
&#xD;
          -  Diabetes of other or unclear etiology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>14 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mishaela Rubin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rukshana Majeed, BA</last_name>
    <phone>2123059489</phone>
    <email>rm3324@columbia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatriz Omeragic Clinical Research Coordinator, BA</last_name>
    <phone>2123057364</phone>
    <email>bo2248@columbia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Columbia University Medical Center-Harkness Pavillion</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rukshana Majeed, BA</last_name>
      <phone>212-305-9489</phone>
      <email>rm3324@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Mishaela Rubin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 2, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Mishaela Rubin</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

